Sight Sciences (SGHT) AI Stock Analysis

• Market Cap: $213.86M
• Dividend Yield: N/A
• Average Volume (3M): 150.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: -4.39%
• EPS Growth: 11.70%
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.08
• Shares Outstanding: 54,005,985
• 10 Day Avg. Volume: 244,568
• 30 Day Avg. Volume: 150,613
• PEG Ratio: 0.38
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 5.35
• P/FCF Ratio: -13.82
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 2.04
• Enterprise Value/Gross Profit: 2.37
• Enterprise Value/Ebitda: -4.68
• 1Y Price Target: $9.30
• Price Target Upside: 134.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.6
• Revenue Forecast (FY): $86.08M

• Rating: 47 Neutral
• Price Target: $5.50 ▲(38.89% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held down primarily by weak financial performance—persistent losses and ongoing negative free cash flow—despite strong gross margins and revenue scale-up. Earnings-call execution improved (cost discipline, narrowing losses, and 2026 growth guidance with a reimbursement catalyst), but technicals remain soft with negative momentum and the valuation is constrained by a negative P/E.

Positive Factors

High gross margins

Sustained mid-to-high 80s gross margins indicate a highly profitable product mix and strong unit economics for devices and consumables. High contribution margins create durable operating leverage potential as installed base and procedure volumes grow, supporting future investment and margin expansion.

Revenue scale and growth track

Multi-year revenue scaling demonstrates meaningful market adoption of OMNI and related consumables. Re-acceleration in 2025 and management's $82–88M 2026 guidance provide a durable foundation for operating leverage if the company sustains adoption and converts more accounts to recurring procedure volumes.

Reimbursement milestone for TearCare

Securing CPT coding from two MACs is a structural change that reduces provider economic barriers and enables a reimbursed commercial model. Reimbursement expands the addressable market for TearCare and strengthens the pathway to recurring consumable revenue if coverage is extended broadly.

Negative Factors

Persistent negative cash flow

Consistent negative operating and free cash flow indicates the business still requires external funding or rapid operational improvement to reach self-sufficiency. Worsening FCF in 2025 constrains optionality for R&D and commercial investment and increases dilution or refinancing risk absent a clear path to profitability.

Eroding equity base

Material decline in equity coupled with outstanding debt reduces financial flexibility and increases leverage metrics, even if absolute debt is moderate. A shrinking capital base limits the company's ability to absorb setbacks, raises refinancing vulnerability, and heightens pressure to achieve profitable growth.

Dry eye business still nascent

Despite reimbursement progress, TearCare revenue is currently very small and dependent on further payer wins and commercial scale. Slow uptake or delayed MAC adoption would limit recurring consumable revenues and materially slow the envisioned diversification of revenue away from core glaucoma products.

Sight Sciences Business Overview & Revenue Model

Company Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

How the Company Makes Money

Sight Sciences generates revenue primarily through the sale of its medical devices and surgical systems to hospitals, outpatient surgical centers, and eye care professionals. The company's key revenue streams include direct sales of its OMNI Surgical System and related consumable products, which are used in glaucoma surgeries. Additionally, Sight Sciences may benefit from strategic partnerships with healthcare providers and distributors, which can enhance its market reach and facilitate the adoption of its technologies. Ongoing investments in research and development also position the company to introduce new products and expand its offerings, contributing to long-term revenue growth.

Sight Sciences Financial Statement Overview

Summary

Revenue has scaled over the multi-year period and gross margins are very strong (mid-to-high 80s), but the company remains consistently unprofitable with ongoing operating/net losses. Cash flow is the biggest drag: operating cash flow and free cash flow are negative across the period with 2025 free cash flow worsening to about -$29.9M, implying continued reliance on funding. The balance sheet leverage is manageable, but equity has fallen materially, increasing risk if profitability does not improve.

Income Statement

Revenue scaled meaningfully over the period (from about $27.6M in 2020 to $77.4M in 2025), but growth has become volatile—down in 2024 and then re-accelerating sharply in 2025. Profitability remains the core issue: despite consistently strong gross margins (mid‑80% range recently), operating losses and net losses persist each year. The net loss margin improved in 2025 versus prior years, but the business is still far from break-even, which keeps the income statement score below average.

Balance Sheet

Leverage looks manageable on paper with debt around $40M and 2025 debt-to-equity at ~0.63, but the trend is moving in the wrong direction as equity has fallen materially (from ~$232M in 2021 to ~$64M in 2025). Returns on equity are deeply negative across the period, reflecting ongoing losses and erosion of the capital base. Overall, the balance sheet is not highly levered, but shrinking equity and continued losses increase risk over time.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative every year shown. While cash burn improved substantially from 2022–2023 levels, it worsened again in 2025 (free cash flow about -$29.9M), and free cash flow growth turned sharply negative in 2025. A positive note is that free cash flow roughly tracks net loss in recent years (i.e., losses are not being masked by working-capital timing), but the company still requires funding to sustain operations absent a near-term profitability inflection.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	77.36M	79.87M	81.06M	71.33M	48.96M
Gross Profit	66.67M	68.28M	69.17M	58.97M	40.35M
EBITDA	-37.10M	-45.90M	-49.41M	-80.48M	-57.20M
Net Income	-38.43M	-51.51M	-55.55M	-86.24M	-62.96M
Balance Sheet
Total Assets	115.30M	142.84M	166.65M	213.07M	280.19M
Cash, Cash Equivalents and Short-Term Investments	91.97M	120.36M	138.13M	185.00M	260.69M
Total Debt	40.30M	40.36M	35.41M	34.98M	34.21M
Total Liabilities	51.36M	55.32M	46.44M	53.00M	48.08M
Stockholders Equity	63.94M	87.52M	120.22M	160.08M	232.11M
Cash Flow
Free Cash Flow	-29.92M	-22.74M	-47.98M	-76.94M	-53.35M
Operating Cash Flow	-29.69M	-22.35M	-47.18M	-75.97M	-52.54M
Investing Cash Flow	-224.00K	-385.00K	-791.00K	-970.00K	-813.00K
Financing Cash Flow	1.79M	4.96M	1.10M	1.25M	252.53M

Sight Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGHT, the sentiment is Negative. The current price of 3.96 is below the 20-day moving average (MA) of 5.38, below the 50-day MA of 6.41, and below the 200-day MA of 5.11, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 26.30 is Positive, neither overbought nor oversold. The STOCH value of 34.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGHT.

Sight Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	66 Neutral	$116.61M	14.16	4.34%	―	3.36%	-21.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCEL	50 Neutral	$146.42M	-1.98	―	―	20.59%	18.61%
CVRX	50 Neutral	$220.23M	-3.47	-91.88%	―	18.44%	25.42%
SGHT	47 Neutral	$213.86M	-10.76	-57.91%	―	-4.39%	11.70%
LNSR	45 Neutral	$145.84M	-10.02	-422.35%	―	21.02%	-200.88%
TLSI	44 Neutral	$285.30M	-3.80	―	―	49.52%	19.34%

Sight Sciences Corporate Events

Sight Sciences Posts Q4 Growth, Issues 2026 Outlook

On March 4, 2026, Sight Sciences reported fourth-quarter 2025 revenue of $20.4 million, up 7% year-on-year, and full-year 2025 revenue of $77.4 million, down 3% versus 2024, as glaucoma sales were flat and dry eye revenue declined for the year. The company maintained high gross margins of 87% in the quarter and 86% for the year, while cutting full-year operating expenses by 13% and narrowing its net loss to $38.4 million, or $0.74 per share.

Fourth-quarter 2025 results showed a return to growth in Interventional Glaucoma and a sharp pickup in Interventional Dry Eye revenue to $0.7 million, helped by higher pricing and recent reimbursement gains. Operating discipline reduced quarterly cash usage to $0.4 million and left the company with $92 million in cash at year-end, and management framed these trends as strengthening Sight Sciences’ platform as it pursues growth in glaucoma and reimbursed dry eye procedures.

Sight Sciences also issued 2026 guidance, projecting revenue of $82 million to $88 million, implying 6% to 14% growth over 2025 driven by modest gains in glaucoma and a rebound in dry eye revenue to $5 million to $7 million. The company plans to modestly increase adjusted operating expenses in 2026 to fund expanded market access and commercial resources, particularly to scale the reimbursed dry eye market and standalone glaucoma opportunities, signaling continued investment-led growth despite ongoing losses.

The most recent analyst rating on (SGHT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Sight Sciences Extends Menlo Park Headquarters Lease Agreement

On January 29, 2026, Sight Sciences, Inc. executed a second amendment to its headquarters lease with Deerfield Campbell, LLC for office space at 4040 Campbell Avenue in Menlo Park, California, extending the existing lease term by 26 months from November 1, 2026 through December 31, 2028. Under the amended terms, base rent for the extension period will be fully abated for November and December 2026, then rise from $44,915.45 per month beginning January 1, 2027 to $47,621.20 per month by the final two months of 2028, providing the company with continued occupancy of its headquarters under a defined rent escalation schedule that clarifies its longer-term facilities costs and commitments.

The most recent analyst rating on (SGHT) stock is a Sell with a $6.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.